1 completed, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Diffuse Cerebral Sclerosis of Schilder: new trials by email Literature Review of Diffuse Cerebral Sclerosis of Schilder trials Research Report on Diffuse Cerebral Sclerosis of Schilder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 68 | 2020-09-28 | 2026-03-31 |
| Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis BAF312, Placebo - Relapsing-remitting Multiple Sclerosis | Phase 2 | Completed | Novartis Pharmaceuticals | 297 | 2009-03-30 | 2020-01-13 |
Demyelinating Diseases (1) · Drug Resistant Epilepsy (1) · Leigh Disease (1) · MELAS Syndrome (1) · MERRF Syndrome (1) · Mitochondrial Diseases (1) · Mitochondrial encephalopathy (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Nerve Degeneration (1) · Neuromyelitis Optica (1) · Pontocerebellar Hypoplasia Type 6 (1) · Seizures (1) · Status Epilepticus (1)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Demyelinating Autoimmune Diseases, CNS (2) · Immune System Diseases (2) · Leukoencephalopathies (2) · Nervous System Diseases (2) · Brain Diseases, Metabolic (1) · Brain Diseases, Metabolic, Inborn (1) · Carbohydrate Metabolism, Inborn Errors (1) · Cardiovascular Diseases (1) · Cerebral Small Vessel Diseases (1) · Cerebrovascular Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
alpha-tocotrienol quinone (1) · siponimod (1)
Novartis Pharmaceuticals (1) · PTC Therapeutics (1)
Canada (2) · Italy (2) · Poland (2) · Spain (2) · United States (2) · Finland (1) · France (1) · Germany (1) · Hungary (1) · Japan (1) · Norway (1) · Russia (1) · Sweden (1) · Switzerland (1) · Turkey (Türkiye) (1)
2008 (1)